Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9802973 | SHIELD TX | Crystalline forms of ferric maltol |
Oct, 2035
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9248148 | SHIELD TX | Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections |
Mar, 2031
(6 years from now) | |
US10179120 | SHIELD TX | Dosage regimen of ferric trimaltol |
Jan, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 25, 2024 |
Drugs and Companies using FERRIC MALTOL ingredient
NCE-1 date: 26 July, 2023
Market Authorisation Date: 25 July, 2019
Treatment: Method of treating iron deficiency
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7807708 | GALDERMA LABS LP | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
Jul, 2031
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8470871 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(1 year, 20 days from now) | |
US8227507 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(1 year, 20 days from now) | |
US9498465 | GALDERMA LABS LP | Topical compositions in the form of a gel containing a particular solubilized retinoid |
May, 2033
(8 years from now) | |
US9084778 | GALDERMA LABS LP | Topical compositions containing a retinoid of the oil-in-water emulsion type |
May, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 04, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: 05 October, 2023
Market Authorisation Date: 04 October, 2019
Treatment: Method of activating rargamma receptor; Topical treatment of acne vulgaris; Treatment of acne vulgaris
Dosage: CREAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5459163 | SANOFI AVENTIS US | Medicament to combat autoimmune diseases |
Oct, 2012
(12 years ago) | |
US5679709 | SANOFI AVENTIS US | Medicaments to combat autoimmune diseases |
Oct, 2014
(10 years ago) | |
US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(1 year, 9 months from now) | |
US6794410 (Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(2 years from now) | |
US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(5 years from now) | |
US8802735 (Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(6 years from now) | |
US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(9 years from now) | |
US9186346 (Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
M(M-61) | Apr 30, 2024 |
Pediatric Exclusivity(PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(6 years from now) | |
US9550780 | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8524733 (Pediatric) | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(6 years from now) | |
US11666566 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(8 years from now) | |
US9296739 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(8 years from now) | |
US9814708 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(8 years from now) | |
US9233959 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(8 years from now) | |
US9814708 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
US11666566 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
US9550780 (Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
US9233959 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
US9296739 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
US11446291 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(11 years from now) | |
US11564917 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(11 years from now) | |
US10959996 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(11 years from now) | |
US12016858 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(11 years from now) | |
US11357772 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(11 years from now) | |
US11648244 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(11 years from now) | |
US12016858 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
US10959996 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
US11564917 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
US11648244 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
US11446291 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
US11357772 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(11 years from now) | |
US11813232 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(13 years from now) | |
US11179386 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(13 years from now) | |
US11179386 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(13 years from now) | |
US11813232 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-751) | Aug 30, 2020 |
New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
M(M-54) | Jun 24, 2024 |
Pediatric Exclusivity(PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8895601 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2033
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9464071 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2031
(6 years from now) | |
US9902714 | JANSSEN BIOTECH | Quinoxaline derivatives useful as FGFR kinase modulators |
Mar, 2035
(10 years from now) | |
US12037644 | JANSSEN BIOTECH | Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor |
Oct, 2035
(10 years from now) | |
US11684620 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(11 years from now) | |
US10898482 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(11 years from now) | |
US10478494 | JANSSEN BIOTECH | FGFR/PD-1 combination therapy for the treatment of cancer |
Aug, 2036
(11 years from now) | |
US11077106 | JANSSEN BIOTECH | Cancer treatment |
Feb, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 12, 2024 |
New Indication(I-930) | Jan 19, 2027 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: 13 April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic the...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9447106 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(9 years from now) | |
US10927117 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
US11851437 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10570139 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(9 years from now) | |
US11142528 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(9 years from now) | |
US11970500 | BEIGENE | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
US11884674 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
US11591340 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
US11701357 | BEIGENE | Treatment of B cell cancers using a combination comprising Btk inhibitors |
Jun, 2039
(14 years from now) | |
US11786531 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(18 years from now) | |
US11911386 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(18 years from now) | |
US11896596 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(18 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-871) | Aug 31, 2024 |
New Indication(I-874) | Sep 14, 2024 |
New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
New Indication(I-817) | Jan 19, 2026 |
Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
New Indication(I-936) | Mar 07, 2027 |
Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with small lymphocytic lymphoma; Treatment of adult patients with relaps...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7183282 | INTRA-CELLULAR | Substituted heterocycle fused γ-carbolines |
Jun, 2020
(4 years ago) | |
USRE39680 | INTRA-CELLULAR | Substituted heterocycle fused gamma-carbolines |
Jun, 2020
(4 years ago) | |
USRE48825 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(4 years from now) | |
US9586960 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(4 years from now) | |
US8648077 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Dec, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10464938 | INTRA-CELLULAR | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof |
Mar, 2028
(3 years from now) | |
US9199995 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Mar, 2029
(4 years from now) | |
US9168258 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(4 years from now) | |
US9616061 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(4 years from now) | |
US10117867 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(4 years from now) | |
US8598119 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Dec, 2029
(5 years from now) | |
USRE48839 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Aug, 2033
(8 years from now) | |
US9956227 | INTRA-CELLULAR | Method for the treatment of residual symptoms of schizophrenia |
Dec, 2034
(10 years from now) | |
US11026951 | INTRA-CELLULAR | Methods of treating bipolar disorder |
Dec, 2034
(10 years from now) | |
US10960009 | INTRA-CELLULAR | Methods of treating schizophrenia and depression |
Dec, 2034
(10 years from now) | |
US12128043 | INTRA-CELLULAR | Pharmaceutical capsules comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
US11806348 | INTRA-CELLULAR | Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
US11052084 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
US10695345 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
US12070459 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
US11690842 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(14 years from now) | |
US11980617 | INTRA-CELLULAR | Methods of treating acute depression and/or acute anxiety |
Oct, 2039
(14 years from now) | |
US12090155 | INTRA-CELLULAR | Methods |
Jul, 2040
(15 years from now) | |
US11753419 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
Dec, 2040
(16 years from now) | |
US12122792 | INTRA-CELLULAR | Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
Dec, 2040
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-882) | Dec 17, 2024 |
New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of schizophrenia; Treatment of schizophrenia with improvement in residual symptoms of...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7119061 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(1 year, 17 days ago) | |
US7115564 | ABBVIE | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(1 year, 17 days ago) | |
US8143212 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(1 year, 17 days ago) | |
US6900175 | ABBVIE | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-154) | Jan 20, 2019 |
New Chemical Entity Exclusivity(NCE) | May 23, 2019 |
Generating Antibiotic Incentives Now(GAIN) | May 23, 2024 |
New Patient Population(NPP) | Jul 22, 2024 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 24 May, 2023
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.; Treatment of acute bacterial skin and skin structure infections (absssi) in adult and pediatric patients using a two-dose re...
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9034300 | GISKIT | Composition and method for medical imaging of body cavities |
Oct, 2030
(5 years from now) | |
US9259494 | GISKIT | Composition and method for medical imaging of body cavities |
May, 2035
(10 years from now) | |
US9849199 | GISKIT | Composition and method for medical imaging of body cavities |
Feb, 2036
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 07, 2024 |
Drugs and Companies using AIR POLYMER-TYPE A ingredient
NCE-1 date: 08 November, 2023
Market Authorisation Date: 07 November, 2019
Treatment: Use in sonohysterosalpinography to assess fallopian tube patency
Dosage: FOAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8546143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of a target gene |
Jan, 2022
(2 years ago) | |
US9708610 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(10 months ago) | |
US9708615 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(8 months ago) | |
US10273477 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(8 months ago) | |
US11530408 | ALNYLAM PHARMS INC | Therapeutic compositions |
May, 2024
(6 months ago) | |
US9150605 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Aug, 2025
(8 months from now) | |
US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(3 years from now) | |
US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(5 years from now) | |
US10125364 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(8 years from now) | |
US9133461 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Nov, 2033
(9 years from now) | |
US10119143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(9 years from now) | |
US11028392 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9631193 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
US8822430 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(5 years from now) | |
US8088368 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(5 years from now) | |
US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(5 years from now) | |
US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
US10039779 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(4 years from now) | |
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(4 years from now) | |
US8273341 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(5 years from now) | |
US9511056 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(5 years from now) | |
US8841278 | GILEAD SCIENCES INC | Antiviral compounds |
May, 2030
(5 years from now) | |
US8841278 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
US8088368 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
US8273341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
US9511056 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
US8822430 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2030
(5 years from now) | |
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(6 years from now) | |
US10456414 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(7 years from now) | |
US9393256 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(7 years from now) | |
US9393256 (Pediatric) | GILEAD SCIENCES INC | Methods for treating HCV |
Mar, 2033
(8 years from now) | |
US10039779 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-153) | Nov 12, 2018 |
New Indication(I-718) | Nov 12, 2018 |
New Indication(I-719) | Nov 12, 2018 |
New Indication(I-720) | Nov 12, 2018 |
New Dosing Schedule(D-158) | Feb 12, 2019 |
New Dosing Schedule(D-159) | Feb 12, 2019 |
New Dosing Schedule(D-160) | Feb 12, 2019 |
New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
New Patient Population(NPP) | Apr 07, 2020 |
New Dosing Schedule(D-177) | Nov 15, 2022 |
Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
ODE*(ODE*) | Aug 28, 2026 |
Orphan Drug Exclusivity(ODE-136) | Apr 07, 2024 |
Pediatric Exclusivity(PED) | Oct 07, 2024 |
Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8969377 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(5 years from now) | |
US12016856 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(5 years from now) | |
US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9408840 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder |
Dec, 2029
(5 years from now) | |
US9006281 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
May, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7825246 | BRISTOL-MYERS | Bi-aryl meta-pyrimidine inhibitors of kinases |
Dec, 2026
(2 years from now) | |
US7528143 | BRISTOL-MYERS | Bi-aryl meta-pyrimidine inhibitors of kinases |
Nov, 2031
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8138199 | BRISTOL-MYERS | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
Jun, 2028
(3 years from now) | |
US10391094 | BRISTOL-MYERS | Compositions and methods for treating myelofibrosis |
Jun, 2032
(7 years from now) | |
US11400092 | BRISTOL-MYERS | Methods of treating myeloproliferative disorders |
Sep, 2039
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
Orphan Drug Exclusivity(ODE-259) | Aug 16, 2026 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis; Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 11 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6303661 | MSD SUB MERCK | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
US7459428 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US6890898 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US7078381 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US6699871 | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(2 years ago) | |
US7125873 | MSD SUB MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(2 years ago) | |
US7125873 (Pediatric) | MSD SUB MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 10 months ago) | |
US6699871 (Pediatric) | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 10 months ago) | |
US7326708 (Pediatric) | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(2 years from now) | |
US8414921 | MSD SUB MERCK | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
Jul, 2028
(3 years from now) | |
US8414921 (Pediatric) | MSD SUB MERCK | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
Jan, 2029
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
M(M-244) | Aug 12, 2022 |
M(M-187) | Dec 04, 2023 |
Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 30 March, 2007
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in com...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(1 year, 11 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6303661 | MERCK SHARP DOHME | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
US7459428 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US6890898 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US7078381 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(2 years ago) | |
US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(2 years ago) | |
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 10 months ago) | |
US7125873 (Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 10 months ago) | |
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
M(M-244) | Aug 12, 2022 |
M(M-187) | Dec 04, 2023 |
Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 16 October, 2006
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin....
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(4 years from now) | |
US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
New Product(NP) | Mar 12, 2024 |
Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 12 March, 2021
Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7939519 | NOVARTIS | Immunosuppresant compounds and compositions |
Aug, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8492441 | NOVARTIS | Dosage regimen of an S1P receptor agonist |
Nov, 2030
(6 years from now) | |
US12071402 | NOVARTIS | Immunosuppressant formulations |
Jan, 2032
(7 years from now) | |
US11944602 | NOVARTIS | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
Jul, 2036
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 26, 2024 |
M(M-274) | Mar 01, 2025 |
Drugs and Companies using SIPONIMOD ingredient
NCE-1 date: 27 March, 2023
Market Authorisation Date: 26 March, 2019
Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically ...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11786548 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
US11998565 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) | |
US11975022 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 30, 2024 |
Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient
NCE-1 date: 01 May, 2023
Market Authorisation Date: 30 June, 2021
Treatment: Neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or ...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6699503 | APGDI | Hydrogel-forming sustained-release preparation |
Sep, 2013
(11 years ago) | |
US6346532 | APGDI | Amide derivatives or salts thereof |
Oct, 2018
(6 years ago) | |
US6562375 | APGDI | Stable pharmaceutical composition for oral use |
Aug, 2020
(4 years ago) | |
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(2 years ago) | |
US8835474 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(1 year, 27 days ago) | |
US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(1 year, 27 days ago) | |
US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(1 year, 27 days ago) | |
USRE44872 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(1 year, 27 days ago) | |
US7750029 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Dec, 2023
(11 months ago) | |
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(6 months ago) | |
US8835474 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(6 months ago) | |
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(6 months ago) | |
USRE44872 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(6 months ago) | |
US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(3 years from now) | |
US8772315 (Pediatric) | APGDI | Pharmaceutical composition for treating overactive bladder |
Apr, 2029
(4 years from now) | |
US12059409 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
US12097189 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
US11707451 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
US10842780 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(5 years from now) | |
US11707451 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
New Indication(I-777) | Apr 27, 2021 |
New Indication(I-855) | Mar 25, 2024 |
Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Treatment of overactive bladder with symptoms of urge urinary incontinence, ur...
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7541363 | KYOWA KIRIN | Microcrystal |
Nov, 2024
(17 days ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7727994 | KYOWA KIRIN | Methods of treating patients suffering from movement disorders |
Jan, 2023
(1 year, 10 months ago) | |
US8318201 | KYOWA KIRIN | Method of stabilizing diarylvinylene compound |
Sep, 2027
(2 years from now) | |
US7727993 | KYOWA KIRIN | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
Jan, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 28 August, 2023
Market Authorisation Date: 27 August, 2019
Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10711013 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(5 years from now) | |
US11046713 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(5 years from now) | |
US9657003 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(5 years from now) | |
US8975254 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Mar, 2033
(8 years from now) | |
US10383853 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(11 years from now) | |
US10010530 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(11 years from now) | |
US11168058 | BAYER HEALTHCARE | Manufacture of a crystalline pharmaceutical product |
Feb, 2038
(13 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10835515 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 30, 2024 |
New Indication(I-900) | Aug 05, 2025 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: 31 July, 2023
Market Authorisation Date: 30 July, 2019
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5998581 | MELINTA THERAP | Reductive alkylation of glycopeptide antibiotics |
Nov, 2017
(7 years ago) | |
US5840684 | MELINTA THERAP | Glycopeptide antibiotic derivatives |
Nov, 2020
(4 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(4 years from now) | |
US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(5 years from now) | |
US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 06 August, 2014
Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10034879 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(8 years from now) | |
US10806733 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(8 years from now) | |
US9018210 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Nov, 2033
(8 years from now) | |
US9447071 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10017491 | GLOBAL BLOOD THERAPS | Compounds and uses thereof for the modulation of hemoglobin |
Dec, 2032
(8 years from now) | |
US9248199 | GLOBAL BLOOD THERAPS | 1:1 adducts of sickle hemoglobin |
Jan, 2034
(9 years from now) | |
US11452720 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(10 years from now) | |
US10722502 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(10 years from now) | |
US11944612 | GLOBAL BLOOD THERAPS | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Dec, 2036
(12 years from now) | |
US11020382 | GLOBAL BLOOD THERAPS | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Dec, 2036
(12 years from now) | |
US10493035 | GLOBAL BLOOD THERAPS | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Oct, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 25, 2024 |
Orphan Drug Exclusivity(ODE-281) | Nov 25, 2026 |
Orphan Drug Exclusivity(ODE-394) | Dec 17, 2028 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: 26 November, 2023
Market Authorisation Date: 14 October, 2022
Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 2; Treating sickle cell disease by administering voxelotor and another active agent; Treatment of sickle cell disease b...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(4 years from now) | |
US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
New Indication(I-937) | Jan 18, 2027 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 24 May, 2019
Treatment: In combination with fulvestrant for treatment of adults with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6087380 | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Dec, 2021
(2 years ago) | |
US7932273 | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Sep, 2025
(9 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6087380 | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Feb, 2018
(6 years ago) | |
US6087380 (Pediatric) | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Jun, 2022
(2 years ago) | |
US9925174 | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Jun, 2023
(1 year, 5 months ago) | |
US9925174 (Pediatric) | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Dec, 2023
(11 months ago) | |
US7932273 (Pediatric) | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Mar, 2026
(1 year, 3 months from now) | |
US7866474 | BOEHRINGER INGELHEIM | Film container |
Aug, 2027
(2 years from now) | |
US7866474 (Pediatric) | BOEHRINGER INGELHEIM | Film container |
Mar, 2028
(3 years from now) | |
US9034822 | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jan, 2031
(6 years from now) | |
US9034822 (Pediatric) | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jul, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 19, 2015 |
New Indication(I-682) | Apr 04, 2017 |
New Indication(I-683) | Apr 04, 2017 |
M(M-168) | Nov 20, 2018 |
New Strength(NS) | Nov 20, 2018 |
New Indication(I-862) | Jun 21, 2024 |
New Product(NP) | Jun 21, 2024 |
Pediatric Exclusivity(PED) | Dec 21, 2024 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
NCE-1 date: 22 December, 2023
Market Authorisation Date: 19 October, 2010
Treatment: Inhibition of thrombin; Method of reversing the anticoagulant effect of dabigatran using idarucizumab; Prophylaxis or treatment of venous and arterial thrombotic disease
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8962629 | ABBVIE | Tricyclic compounds |
Jan, 2031
(6 years from now) | |
USRE47221 | ABBVIE | Tricyclic compounds |
Aug, 2033
(8 years from now) | |
US10981923 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11186584 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11773105 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11661425 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11680069 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US9951080 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11718627 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11365198 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11198697 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US10344036 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US10202393 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US10981924 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US12091415 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US12077545 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11787815 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11780847 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US9963459 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US10730883 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11780848 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US10519164 | ABBVIE | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US10597400 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US10995095 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11767326 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11795175 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11512092 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11524964 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11976077 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof |
Oct, 2036
(11 years from now) | |
US10550126 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11535624 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11535625 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11535626 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11773106 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11993605 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11993606 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US12103933 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11564922 | ABBVIE | Methods of treating crohn's disease and ulcerative colitis |
Mar, 2038
(13 years from now) | |
US11607411 | ABBVIE | Methods of treating Crohn's disease and ulcerative colitis |
Mar, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
New Indication(I-880) | Dec 14, 2024 |
New Indication(I-883) | Jan 14, 2025 |
New Indication(I-886) | Mar 16, 2025 |
New Indication(I-888) | Apr 29, 2025 |
New Indication(I-919) | May 18, 2026 |
New Indication(I-946) | Apr 26, 2027 |
New Patient Population(NPP) | Apr 26, 2027 |
Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active ankylosing spondylitis who have had ...
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8962629 | ABBVIE | Tricyclic compounds |
Jan, 2031
(6 years from now) | |
USRE47221 | ABBVIE | Tricyclic compounds |
Aug, 2033
(8 years from now) | |
US11680069 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US10981923 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US9951080 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11718627 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11661425 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11773105 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US11186584 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) | |
US12110298 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
New Product(NP) | Apr 26, 2027 |
Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 26 April, 2024
Treatment: Treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tnf blockers
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9029356 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
US8299057 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Mar, 2029
(4 years from now) | |
US9085565 | GENENTECH INC | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(8 years from now) | |
US10738037 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9085558 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
US9616059 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
US8673893 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
US9255087 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
US9649306 | GENENTECH INC | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(8 years from now) | |
US10231965 | GENENTECH INC | Molecules for administration to ROS1 mutant cancer cells |
Feb, 2035
(10 years from now) | |
US10561651 | GENENTECH INC | Methods for treating neuroblastoma |
Feb, 2035
(10 years from now) | |
US11091469 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(12 years from now) | |
US11253515 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(13 years from now) | |
US10398693 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 15, 2024 |
Orphan Drug Exclusivity(ODE-265) | Aug 15, 2026 |
Orphan Drug Exclusivity(ODE-313) | Aug 15, 2026 |
New Product(NP) | Oct 20, 2026 |
New Patient Population(NPP) | Oct 20, 2026 |
Orphan Drug Exclusivity(ODE-448) | Oct 20, 2030 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 16 August, 2023
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; Treatment of neuroblastomas that have a neurotrop...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10076555 | CLIVUNEL INC | Methods of inducing melanogenesis in a subject |
Feb, 2025
(2 months from now) | |
US8334265 | CLIVUNEL INC | Method of treatment of photodermatoses |
Mar, 2029
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 08, 2024 |
Orphan Drug Exclusivity(ODE-270) | Oct 08, 2026 |
Drugs and Companies using AFAMELANOTIDE ingredient
NCE-1 date: 09 October, 2023
Market Authorisation Date: 08 October, 2019
Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)
Dosage: IMPLANT
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11998565 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 30, 2024 |
Drugs and Companies using SELENIOUS ACID ingredient
NCE-1 date: 01 May, 2023
Market Authorisation Date: 30 August, 2021
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8420676 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Feb, 2028
(3 years from now) | |
US7816379 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Jun, 2028
(3 years from now) | |
US10442829 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) | |
US9624250 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) | |
US8426389 | CUBIST PHARMS LLC | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Dec, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9988406 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) | |
US10065947 | CUBIST PHARMS LLC | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 20, 2019 |
New Patient Population(NPP) | Jun 19, 2023 |
Generating Antibiotic Incentives Now(GAIN) | Jun 20, 2024 |
Drugs and Companies using TEDIZOLID PHOSPHATE ingredient
NCE-1 date: 21 June, 2023
Market Authorisation Date: 20 June, 2014
Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria
Dosage: POWDER; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(5 years from now) | |
US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
US9549941 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(4 years from now) | |
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(4 years from now) | |
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
US9549941 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
New Patient Population(NPP) | Apr 07, 2020 |
Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
ODE*(ODE*) | Aug 28, 2026 |
Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
Pediatric Exclusivity(PED) | Oct 07, 2024 |
Orphan Drug Exclusivity(ODE-258) | Aug 28, 2026 |
Drugs and Companies using SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9604917 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 6 months from now) | |
US8877806 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 6 months from now) | |
US11753368 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 6 months from now) | |
US10351517 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(1 year, 6 months from now) | |
US8440715 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2031
(6 years from now) | |
US10512609 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
US10195151 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
US11998639 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
US11648232 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
US10959976 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
US11865098 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
US10912754 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(13 years from now) | |
US11560354 | AXSOME MALTA | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof |
Mar, 2039
(14 years from now) | |
US11850226 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
US11850227 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
US11850228 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
US11857528 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
US11986455 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
US11986454 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
US11839598 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
US11839599 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
US11969404 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
US11160779 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
US10940133 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(15 years from now) | |
US12102609 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
US12064411 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
US12005036 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
US11771667 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
US11771666 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
US11872204 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
US11872203 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
US12036194 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
US11779554 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
US12090126 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
US11793776 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness with a dosing regimen ...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7855230 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(5 years ago) | |
US7985772 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(5 years ago) | |
US7384980 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(5 years ago) | |
US8338478 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(5 years ago) | |
US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(2 years ago) | |
US6858650 (Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(1 year, 10 months ago) | |
US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(2 years from now) | |
US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(2 years from now) | |
US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(2 years from now) | |
US8088398 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(3 years from now) | |
US7807715 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(3 years from now) | |
US8501723 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 31, 2013 |
New Indication(I-861) | Jun 17, 2024 |
Pediatric Exclusivity(PED) | Dec 17, 2024 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
NCE-1 date: 18 December, 2023
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE